Bavarian Nordic (BAVA) Stock Overview
Develops, manufactures, and supplies life-saving vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BAVA Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 180.40 |
| 52 Week High | DKK 300.00 |
| 52 Week Low | DKK 123.30 |
| Beta | 1.2 |
| 1 Month Change | 13.85% |
| 3 Month Change | 7.70% |
| 1 Year Change | -0.72% |
| 3 Year Change | -11.53% |
| 5 Year Change | -4.70% |
| Change since IPO | -29.25% |
Recent News & Updates
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet
Apr 03
Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear
Mar 13Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 08
Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks
The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely
Dec 14Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Nov 16Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Aug 26Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Aug 25Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly
Aug 09Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit
Jul 11Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 12Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Feb 26Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry
Jan 03Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 10Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly
Nov 15Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Aug 17Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 19Shareholder Returns
| BAVA | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 4.3% | 3.9% | 2.8% |
| 1Y | -0.7% | -23.2% | -30.9% |
Return vs Industry: BAVA exceeded the Danish Biotechs industry which returned -24.7% over the past year.
Return vs Market: BAVA exceeded the Danish Market which returned -32.1% over the past year.
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DK Market | 9.7% |
| 10% least volatile stocks in DK Market | 3.6% |
Stable Share Price: BAVA has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: BAVA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,645 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | DKK 14.04b |
| Earnings (TTM) | DKK 1.32b |
| Revenue (TTM) | DKK 6.23b |
Is BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | DKK 6.23b |
| Cost of Revenue | DKK 3.00b |
| Gross Profit | DKK 3.23b |
| Other Expenses | DKK 1.91b |
| Earnings | DKK 1.32b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 22, 2025
| Earnings per share (EPS) | 16.97 |
| Gross Margin | 51.90% |
| Net Profit Margin | 21.20% |
| Debt/Equity Ratio | 0.1% |
How did BAVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 06:49 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bavarian Nordic A/S is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |